

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Bloomage BioTechnology Corporation Limited**

**華熙生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 00963)**

### **ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE**

This announcement is made by Bloomage BioTechnology Corporation Limited (the “**Company**”) pursuant to Rule 3.8 of the Hong Kong Code on Takeovers and Mergers (the “**Takeovers Code**”). References are made to the joint announcement of the Company and Grand Full Development Limited (the “**Offeror**”) dated 19 June 2017 and the scheme document jointly issued by the Company and the Offeror dated 15 September 2017 (the “**Scheme Document**”). Capitalized terms used herein shall have the same meanings as those defined in the Scheme Document.

### **UPDATE OF NUMBER OF RELEVANT SECURITIES OF THE COMPANY**

The Board wishes to announce that, on 4 October 2017, 120,000 new Shares were allotted and issued due to the exercise of 120,000 Share Options granted under the Share Option Scheme at the exercise price of HK\$4.422 per Share.

Details of all classes of “relevant securities” (as defined in note 4 to Rule 22 of the Takeovers Code) issued by the Company and the numbers of such securities in issue as at the date of this announcement are as follows:

- (a) a total of 366,505,834 Shares are in issue;
- (b) a total of 13,136,700 outstanding Share Options granted under the Share Option Scheme with rights to subscribe for a total of 13,136,700 new Shares;
- (c) a total of 16,600,000 outstanding Warrants with rights to subscribe for a total of 16,600,000 new Shares; and
- (d) the outstanding Convertible Bonds convertible into Shares at the initial conversion price of HK\$17.20 per Share, subject to adjustments.

As at the date of this announcement, save as disclosed above, the Company has no outstanding securities, options, derivatives or warrants which are convertible or exchangeable into Shares and the Company has no other relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code).

## **DISCLOSURE OF DEALINGS**

The respective associates of the Offeror and the Company are hereby reminded to disclose their dealings in any securities of the Company in accordance to Rule 22 of the Takeovers Code.

Pursuant to Note 11 to Rule 22 of the Takeovers Code, stockbrokers, banks and others who deal in relevant securities on behalf of clients have a general duty to ensure, so far as they are able, that those clients are aware of the disclosure obligations attaching to associates and other persons under Rule 22 of the Takeovers Code and that those clients are willing to comply with them. Principal traders and dealers who deal directly with investors should, in appropriate cases, likewise draw attention to the relevant rules of the Takeovers Code. However, this does not apply when the total value of dealings (excluding stamp duty and commission) in any relevant security undertaken for a client during any 7 day period is less than HK\$1 million.

This dispensation does not alter the obligation of principals, associates and other persons themselves to initiate disclosure of their own dealings, whatever total value is involved.

Intermediaries are expected to co-operate with the Executive in its dealings enquiries. Therefore, those who deal in relevant securities should appreciate that stockbrokers and other intermediaries will supply the Executive with relevant information as to those dealings, including identities of clients, as part of that co-operation.

**WARNING: Shareholders and potential investors generally should exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor or other professional advisers.**

By Order of the Board of  
**Bloomage BioTechnology Corporation Limited**  
華熙生物科技有限公司  
**Gong Anmin**  
*Director*

Hong Kong, 4 October 2017

*As at the date of this announcement, the Directors are:*

*Executive Directors:*

*Ms. Zhao Yan*

*Mr. Jin Xuekun*

*Mr. Gong Anmin*

*Ms. Wang Aihua*

*Non-executive Director:*

*Mr. Yau Wai Yan*

*Independent non-executive Directors:*

*Ms. Zhan Lili*

*Mr. Li Junhong*

*Mr. Xue Zhaofeng*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statement in this announcement misleading.*